{"title":"益生菌恢复肠内HDL3分泌，改善终末期肾病患者预后","authors":"Xiaoxue Liu, Yuan Huang, Yixuan Li, Juan Chen, Xifan Wang, Xiaobin Wang, Liang Zhao, Yongting Luo, Peng An, Liwei Zhang, Chengying Zhang, Weijing Bian, Xingen Lei, Xiang Gao, Yinghua Liu, Yanling Hao, Huiyuan Guo, Xiaoxu Zhang, Pengjie Wang, Ran Wang, Hao Zhang, Bing Fang, Xiaolin Zhang, Longjiao Wang, Qinglu Qiu, Yuchan Zhang, Jingyi Qi, Songtao Yang, Yulong Yin, Fazheng Ren, Xiaoyu Wang","doi":"10.1002/imt2.70062","DOIUrl":null,"url":null,"abstract":"<p>Randomized double-blind trials have shown that probiotic mixtures significantly increase high-density lipoprotein (HDL) levels and reduce the risk of cardiovascular disease mortality in end-stage renal disease (ESRD) patients. Meta-analysis with prospective cohort studies further confirms that elevated HDL is a protective factor for ESRD outcomes. In severe renal injury models, including 5/6 nephrectomy and apolipoprotein E-deficient (<i>ApoE<sup>−/−</sup></i>) mice, probiotics restored cardiac function, mirroring the cardioprotective effects seen in humans. Mechanistic studies indicate that probiotics enhance intestinal HDL3 production through the insulin-mediated SP1(P)-CYP27A-LXRα/β-ABCA1 pathway, thereby maintaining HDL metabolic homeostasis. This study reveals a novel link between probiotic intervention and host cholesterol metabolism, offering a previously unexplored strategy for reducing cardiovascular risk in ESRD patients.\n\n <figure>\n <div><picture>\n <source></source></picture><p></p>\n </div>\n </figure></p>","PeriodicalId":73342,"journal":{"name":"iMeta","volume":"4 4","pages":""},"PeriodicalIF":23.7000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.70062","citationCount":"0","resultStr":"{\"title\":\"Probiotics restore enteric HDL3 secretion and improve prognosis in patients with end-stage renal disease\",\"authors\":\"Xiaoxue Liu, Yuan Huang, Yixuan Li, Juan Chen, Xifan Wang, Xiaobin Wang, Liang Zhao, Yongting Luo, Peng An, Liwei Zhang, Chengying Zhang, Weijing Bian, Xingen Lei, Xiang Gao, Yinghua Liu, Yanling Hao, Huiyuan Guo, Xiaoxu Zhang, Pengjie Wang, Ran Wang, Hao Zhang, Bing Fang, Xiaolin Zhang, Longjiao Wang, Qinglu Qiu, Yuchan Zhang, Jingyi Qi, Songtao Yang, Yulong Yin, Fazheng Ren, Xiaoyu Wang\",\"doi\":\"10.1002/imt2.70062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Randomized double-blind trials have shown that probiotic mixtures significantly increase high-density lipoprotein (HDL) levels and reduce the risk of cardiovascular disease mortality in end-stage renal disease (ESRD) patients. Meta-analysis with prospective cohort studies further confirms that elevated HDL is a protective factor for ESRD outcomes. In severe renal injury models, including 5/6 nephrectomy and apolipoprotein E-deficient (<i>ApoE<sup>−/−</sup></i>) mice, probiotics restored cardiac function, mirroring the cardioprotective effects seen in humans. Mechanistic studies indicate that probiotics enhance intestinal HDL3 production through the insulin-mediated SP1(P)-CYP27A-LXRα/β-ABCA1 pathway, thereby maintaining HDL metabolic homeostasis. This study reveals a novel link between probiotic intervention and host cholesterol metabolism, offering a previously unexplored strategy for reducing cardiovascular risk in ESRD patients.\\n\\n <figure>\\n <div><picture>\\n <source></source></picture><p></p>\\n </div>\\n </figure></p>\",\"PeriodicalId\":73342,\"journal\":{\"name\":\"iMeta\",\"volume\":\"4 4\",\"pages\":\"\"},\"PeriodicalIF\":23.7000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imt2.70062\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"iMeta\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/imt2.70062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"iMeta","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imt2.70062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Probiotics restore enteric HDL3 secretion and improve prognosis in patients with end-stage renal disease
Randomized double-blind trials have shown that probiotic mixtures significantly increase high-density lipoprotein (HDL) levels and reduce the risk of cardiovascular disease mortality in end-stage renal disease (ESRD) patients. Meta-analysis with prospective cohort studies further confirms that elevated HDL is a protective factor for ESRD outcomes. In severe renal injury models, including 5/6 nephrectomy and apolipoprotein E-deficient (ApoE−/−) mice, probiotics restored cardiac function, mirroring the cardioprotective effects seen in humans. Mechanistic studies indicate that probiotics enhance intestinal HDL3 production through the insulin-mediated SP1(P)-CYP27A-LXRα/β-ABCA1 pathway, thereby maintaining HDL metabolic homeostasis. This study reveals a novel link between probiotic intervention and host cholesterol metabolism, offering a previously unexplored strategy for reducing cardiovascular risk in ESRD patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
